Month: March 2020

13. marts 2020Selskabsmeddelelse nr. 20/2020Aktietilbagekøbsprogram afsluttetAlm. Brand A/S har i perioden 30. april 2019 til 12. marts 2020 gennemført et aktietilbagekøbsprogram på op til 200 mio.kr.Aktietilbagekøbsprogrammet blev annonceret og nærmere beskrevet ved selskabsmeddelelse nr. 26/2019.Aktietilbagekøbsprogrammet er gennemført i overensstemmelse med EU-Kommissionens forordning nr. 596/2014 af 16. april 2014 (Markedsmisbrugsforordningen) og er varetaget af Danske Bank A/S.Tilbagekøbsprogrammet er afsluttet 12. marts 2020 med udsendelse af selskabsmeddelelse nr. 19/2020, hvor detaljerede transaktionsdata fremgår i overensstemmelse med Kommissionens delegerede forordning (EU) 2016/1052 af 8. marts 2016.Det samlede opkøb i henhold til tilbagekøbsprogrammet er 3.546.087 stk. aktier til en gennemsnitlig købskurs på 56,40 kr. pr. stk....

PWC er eftirlitsaðili skuldabréfaflokkanna HEIMA071225, HEIMA071248 og HEIMA100646.Eftirlitsaðili hefur m.a. það hlutverk að kanna og staðfesta sjálfstæða útreikninga útgefanda á sérstökum skilyrðum skuldabréfaflokkanna.PwC framkvæmdi könnun á útreikningum sérstakra skilyrða skuldabréfaflokkanna  HEIMA071225, HEIMA071248 og HEIMA100646.Niðurstaða könnunar PwC er sú að PwC staðfestir að skuldabréfaflokkarnir HEIMA071225, HEIMA071248 og HEIMA100646 standast öll fjárhagsleg-og tryggingarleg skilyrði skuldabréfaflokkanna miðað við dagsetninguna 31.12.2019.Niðurstöðurnar má sjá hér í viðhendi.Nánari upplýsingar veitir:Arnar Gauti Reynisson, framkvæmdastjóri Heimavalla hf.,Gauti@heimavellir.is, s:860-5300ViðhengiPwC staðfesting vegna 071225 31.12.2019PwC staðfesting vegna 100646 31.12.2019PwC staðfesting vegna 071248 31.12.2019

WisdomTree Multi Asset Issuer PLCLEI: 2138003QW2ZAYZODBU2313 March 2020WisdomTree Multi Asset Issuer PLC(the “Issuer”)Compulsory Redemption of WisdomTree WTI Crude Oil 3x Daily Leveraged and WisdomTree Brent Crude Oil 3x Daily Leveraged (the “Impacted Products”)Further to the announcement made by the Issuer on 9 March 2020 (the “Original Notice”), the Issuer confirms that the relevant Compulsory Redemption Amounts per ETP Security for the Impacted Products are as follows:The base currency for the both Impacted Products is USD and therefore the Compulsory Redemption Amount per ETP Security is calculated in USD. The Issuer will pay out such amounts in USD on or around the 18 March 2020 (being the “Compulsory Redemption Settlement Date”). The settlement of cash redemption proceeds due to Security Holders holding the relevant Impacted Products...

BUFFALO, N.Y., March 13, 2020 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today provides an update on the Company’s operations in light of the recent declaration of the coronavirus outbreak a pandemic.Athenex’s operational plans continue to remain on track and the Company’s current assessment is that the NDA submission for Oral Paclitaxel and pre-launch preparations for Oral Paclitaxel and tirbanibulin ointment should not be impacted. In addition, the Company’s interactions with the U.S. FDA and other regulatory authorities currently remain on schedule. While Athenex’s China operations in Chongqing were impacted by the coronavirus situation, the Company is delighted...

THE WOODLANDS, Texas, March 13, 2020 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today additional data on XERMELO’s® (telotristat ethyl) antiproliferative effects in patients with carcinoid syndrome that were presented at the European Neuroendocrine Tumor Society (ENETS) meeting (March 11-13). XERMELO is approved for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy, but is not currently approved for any other use.Data from a retrospective, pre- and post-design chart review of 200 metastatic neuroendocrine tumor patients who were on standard background therapies and received telotristat ethyl for an average of 12 months in US clinical practice demonstrated that most patients had no tumor progression at...